Verrica's VP-102 Application Review for Molluscum Contagiosum Delayed till September

by Vandana Singh, Benzinga Editor

May 28, 2021 8:42 AM | 29 seconds read | Make a Comment

The FDA has extended the review period for the marketing application for Verrica Pharmaceuticals Inc's VRCA VP-102 to treat molluscum contagiosum (molluscum).
Now the Prescription Drug User Fee Act (PDUFA) goal date is September 23.
The FDA extended the review period to have additional time for the information submitted by Verrica, including its training program and distribution model, in response to comments from the agency regarding the Company's human factors study.
Price Action: VRCA shares are down 3.82% at $11.33 in the premarket session on the last check Friday.

Posted In: Biotech News Health Care Small Cap FDA General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.